TGFBI, Polyclonal Antibody

TGFBI; transforming growth factor, beta-induced, 68kDa; BIGH3; CDB1; CDG2; CDGG1; CSD; CSD1; CSD2; CSD3; EBMD; LCD1; RGD-containing collagen-associated protein; kerato-epithelin; BIGH3 antibody; CDB1 antibody; CDG2 antibody; CDGG1 antibody; CSD antibody; CSD1 antibody; CSD2 antibody; CSD3 antibody; EBMD antibody; kerato-epithelin antibody; LCD1 antibody; RGD-containing collagen-associated protein antibody; transforming growth factor; beta-induced; 68kDa antibody; TGFBI antibody

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul (lot specific)

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-TGFBI antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Peptide ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC)

Peptide ELISA: Antibody detection limit dilution 1: 32000.
Immunohistochemistry: In paraffin embedded Kidney shows staining of intercalated cells of a collecting tubule. Recommended concentration, 4-6ug/ml.
Western Blot: Approx 70kDa band observed in Human, Mouse and Rat Kidney lysates (calculated MW of 74.7kDa according to Human NP_000349.1). Recommended concentration: 0.2-0.5ug/ml.

(0.3ug/ml) staining of Human Kidney lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

(3.8ug/ml) staining of paraffin embedded Human Kidney. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.

74,681 Da

transforming growth factor beta induced

transforming growth factor-beta-induced protein ig-h3

Transforming growth factor-beta-induced protein ig-h3

BIGH3; Beta ig-h3; RGD-CAP  [Similar Products]

BGH3_HUMAN

This gene encodes an RGD-containing protein that binds to type I, II and IV collagens. The RGD motif is found in many extracellular matrix proteins modulating cell adhesion and serves as a ligand recognition sequence for several integrins. This protein plays a role in cell-collagen interactions and may be involved in endochondrial bone formation in cartilage. The protein is induced by transforming growth factor-beta and acts to inhibit cell adhesion. Mutations in this gene are associated with multiple types of corneal dystrophy. [provided by RefSeq, Jul 2008]

betaIG-H3: Binds to type I, II, and IV collagens. This adhesion protein may play an important role in cell-collagen interactions. In cartilage, may be involved in endochondral bone formation. By TGFB1. Highly expressed in the corneal epithelium.

Protein type: Extracellular matrix; Cell adhesion; Secreted, signal peptide; Secreted

Chromosomal Location of Human Ortholog: 5q31

Cellular Component: basement membrane; extracellular matrix; extracellular region; extracellular space; plasma membrane; proteinaceous extracellular matrix; trans-Golgi network

Molecular Function: collagen binding; extracellular matrix binding; integrin binding; protein binding

Biological Process: angiogenesis; cell adhesion; cell proliferation; cellular protein metabolic process; chondrocyte differentiation; extracellular matrix organization and biogenesis; negative regulation of cell adhesion; response to stimulus; visual perception

Disease: Corneal Dystrophy Of Bowman Layer, Type I; Corneal Dystrophy Of Bowman Layer, Type Ii; Corneal Dystrophy, Avellino Type; Corneal Dystrophy, Epithelial Basement Membrane; Corneal Dystrophy, Groenouw Type I; Corneal Dystrophy, Lattice Type I; Corneal Dystrophy, Lattice Type Iiia

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.